Propanc Biopharma Announces Publication of Pilot Study Demonstrating Potent Anti-Tumor Efficacy of PRP Pancreatic Proenzyme Formulation in Pancreatic & Ovarian Cancer
Go back to Propanc Biopharma Announces Publication of Pilot Study Demonstrating Potent Anti-Tumor Efficacy of PRP Pancreatic Proenzyme Formulation in Pancreatic & Ovarian Cancer| (NASDAQ: PPCB) | Delayed: 0.28 +0.01 (3.70%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.27 | 52 Week High | $ | |||
| Open | $0.28 | 52 Week Low | $ | |||
| Day High | $0.28 | P/E | N/A | |||
| Day Low | $0.25 | EPS | $ | |||
| Volume | 252,724 | |||||



